Context: Increased renal sodium reabsorption contributes to hypertension in Cushing syndrome (CS). Renal sodium transporters can be analyzed noninvasively in urinary extracellular vesicles (uEVs).
Main Outcome Measure: Abundance of protein in uEVs.
Results: The 10 patients with CS were divided in those with suppressed and nonsuppressed reninangiotensin-aldosterone system (RAAS; n = 5 per group). Patients with CS with suppressed RAAS had similar blood pressure but significantly lower serum potassium than patients with CS with nonsuppressed RAAS. Compared with healthy participants, only patients with suppressed RAAS had higher phosphorylated Na + -K + -Cl 2 cotransporter type 2 (pNKCC2) and higher total and phosphorylated Na + -Cl 2 cotransporter (pNCC) in uEVs. Serum potassium but not urinary free cortisol correlated with pNKCC2, pNCC, and Na + -Cl 2 cotransporter (NCC) in uEVs. Treatment of CS reversed the increases in pNKCC2, NCC, and pNCC.
Conclusions: CS increases renal sodium transporter abundance in uEVs in patients with hypertension and suppressed RAAS. Potassium has recently been identified as an important driver of NCC activity, and low serum potassium may also contribute to increased renal sodium reabsorption and hypertension in CS. These results may also be relevant for hypertension induced by exogenous glucocorticoids. (J Clin Endocrinol Metab 103: 2583-2591, 2018)
A common clinical feature of Cushing syndrome (CS) is hypertension, which occurs in~75% of patients (1, 2) . Because of the pleiotropic effects of glucocorticoids, the pathogenesis of hypertension in CS is believed along the nephron (9) (10) (11) (12) cotransporter (NCC) in the distal convoluted tubule (10) , and the epithelial sodium channel (ENaC) in the collecting duct (3, 11) . In addition to these sodium transporters expressed at the apical plasma membrane, glucocorticoids can also increase activity of the basolateral Na + -K + -ATPase (13) . Activation of these transport proteins may be mediated through activation of the glucocorticoid receptor, which is expressed throughout the nephron (3, 14) . In addition, supraphysiological concentrations of cortisol can overwhelm the capacity of 11b-hydroxysteroid dehydrogenase type 2 to inactivate cortisol to cortisone. This enables activation of the mineralocorticoid receptor, with subsequent activation of NCC and ENaC. Because ENaC is electrochemically coupled to potassium secretion, CS may cause hypokalemic hypertension, similar to primary aldosteronism (15, 16) . However, mineralocorticoid receptor antagonists do not fully prevent hypertension in CS, suggesting that this mechanism does not fully explain hypertension in CS (15, 17) .
The effects of glucocorticoids on renal sodium transport have mainly been studied in vitro and in experimental animals (9-11, 13, 18) . Isolation of urinary extracellular vesicles (uEVs) in healthy persons and patients now allows for a noninvasive analysis of renal sodium transport. uEVs are nanosized vesicles that can be isolated from human urine and contain renal transport proteins (19) . We previously confirmed in both rats and humans that aldosterone activation of sodium transporters in the kidney results in corresponding changes of these transporters in uEVs (20) . In the current study, we analyze renal sodium transport proteins in uEVs isolated from patients with CS and hypertension. In addition to total abundances, we also analyze the phosphorylated forms of NCC (pNCC) and NKCC2 (pNKCC2), which are considered the active forms of these transporters (21) .
Because ENaC is difficult to analyze in uEVs, we instead analyzed one of its activating serine proteases, prostasin, as has been done previously (20, 22) . Finally, we analyzed the pleiotropic kinase Rac1 because it has been considered a measure of mineralocorticoid receptor activity and is detectable in uEVs (23, 24) .
Materials and Methods

Patients and healthy controls
Our medical ethics committee approved this study (MEC-2007-048 ). All patients gave written informed consent. Consecutive patients with newly diagnosed or recurrent CS in our center were considered for inclusion during the period 2012-2015. ACTH-dependent and ACTH-independent hypercortisolism was biochemically established with measurement of 24-hour urinary cortisol excretion, late-night salivary cortisol, plasma cortisol levels (8:00 AM) after 1 mg dexamethasone overnight, and ACTH concentrations (25) . To analyze renal sodium transporters in uEVs, we excluded patients who were using medication that interferes with renal sodium transport (renin-angiotensin inhibitors or diuretics). Patients with CS were further subdivided into those with or without suppressed plasma renin-angiotensin-aldosterone system (RAAS), as defined by the lower levels of normal for plasma renin (10 mU/mL) and/or aldosterone of (50 pg/mL). The rationale for this was that patients with suppressed RAAS are more likely to have increased renal sodium reabsorption by other mechanisms than the RAAS itself, which may be reflected in uEV transporter status. Biochemical and clinical remission was reached in all patients. For 7 of the 10 patients with CS, urinary samples were available before and after treatment. Healthy participants were recruited and matched to patients with CS by age; they did not use any drugs and had no hypertension or history of endocrine disorders or chronic kidney disease.
Measurements
Blood pressure was measured in the supine position by using an automatic oscillometric device for at least 15 minutes; the average of the last three measurements was used for analysis. Hypertension was defined as systolic blood pressure $ 135 mm Hg and/or diastolic blood pressure $ 85 mm Hg (26) . Both 24-hour urine and spot urine samples were collected. Plasma and urine electrolytes were measured by using an ion-selective electrode (ISE Indirect, Cobas; Roche Diagnostics, Mannheim, Germany). Creatinine was measured by using an enzymatic colorimetric method (Crep2, Cobas; Roche Diagnostics). Renin in plasma was measured by using an immunoradiometric kit (Renin III; Cisbio, Gif-sur-Yvette, France). Aldosterone was measured by solid-phase radioimmunoassay (Diagnostic Products Corp., Los Angeles, CA). Plasma renin and aldosterone were measured midmorning after the patient had been up for at least 2 hours, with blood collection after the patient had been seated for 5 to 15 minutes (27) . Plasma and saliva cortisol were measured by using liquid chromatography coupled to mass spectrometry. Urinary free cortisol is expressed as the fold-elevation above the upper limit of normal.
Isolation and immunoblotting of uEVs
The spot urine samples from which uEVs were isolated were collected around the time of the blood collections. Spot urine samples were collected in a urinary container with a protease inhibitor (cOmplete; Roche, Woerden, The Netherlands) and centrifuged (3000g for 5 minutes) to remove cells and debris before storage at 280°C. The uEVs were isolated by using high speed and ultracentrifugation, as described previously (28, 29) . Briefly, urine was first centrifuged at 17,000g for 15 minutes to pellet high-density particles, separating the supernatant (supernatant 1). Dithiothreitol was then used to disrupt the TammHorsfall polymers, after which the samples were diluted in isolation buffer and centrifuged at 17,000g (supernatant 2) (29). The two supernatants were then combined and ultracentrifuged at 200,000g for 2 hours. The pellets were suspended in Laemmli buffer for immunoblot analysis and subsequently heated at 60°C for 15 minutes. The uEVs of patients with CS and healthy controls were isolated simultaneously. Urine creatinine was used for normalization of spot samples, as done previously (28, 30) . SDS-PAGE was carried out on a gradient gel (4% to 20%), after which the gel was transferred to a TransBlot Turbo system (Bio-Rad, Hercules, CA). The membranes were blocked in 5% milk or BSA and incubated overnight at 4°C. Antibodies against the following proteins were used: NHE3 [1:1000; StressMarq (31) (36)], Na + /K + -ATPase (1:250; Abcam; product # ab7671), and CD9 (1:500; Santa Cruz Biotechnology; product # sc-13118). Secondary antibodies were peroxidase-conjugated goat anti-rabbit or -mouse (1:3000; Sigma-Aldrich). Imaging was obtained by using an Amersham Imager 600 (GE Healthcare, Uppsala, Sweden), and the densitometry measurements were performed by using ImageQuant, version 8.1.0.0 (GE Healthcare, Chicago, IL). All immunoblots were performed twice to verify consistency and reproducibility. CD9 was used as a measure of uEV number (28) . Although urine creatinine and CD9 are highly correlated (28), we did not perform a second normalization on CD9 and did not correct densitometry for CD9. The reason to do so reflects the unresolved issue of whether differences in uEV proteins between groups reflect more protein per uEV or more uEVs expressing this protein.
Statistical analyses
Results are expressed as mean and SD or median and range, as appropriate. Data were logarithmically transformed before analysis in case of non-normal distribution. A Student t test or ANOVA was used for group comparison. A paired t test was used to analyze effects in uEVs before and after treatment.
Pearson correlation was used to analyze correlations between serum levels of potassium or aldosterone to urinary sodium transporters (NCC, pNCC, and NKCC2). A P value , 0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with SPSS software, version 21 (IBM, Armonk, NY).
Results
Patient characteristics
Out of the 18 consecutive patients with CS, 8 were excluded because they used interfering medication. The remaining 10 patients formed the study population (Table 1) . They were compared with seven healthy participants. Eight patients with CS had an ACTH-producing pituitary adenoma (one macroadenoma, seven microadenoma), whereas two patients had a cortisol-producing adrenal adenoma. In the latter patients there was no biochemical evidence for aldosterone cosecretion (low plasma aldosterone levels). The 10 patients with CS were further divided into those with suppressed RAAS and those with nonsuppressed RAAS (Fig. 1) . Patients with CS with suppressed RAAS had significantly lower body mass index (BMI), higher estimated glomerular filtration rate, and lower serum potassium levels. Blood pressure did not differ between the two groups. In each of these groups, one patient used metoprolol.
CS increases renal sodium transporters in uEVs
Total NCC and the phosphorylated forms of NCC and NKCC2 were more abundant only in uEVs of patients with CS and a suppressed RAAS (Fig. 2) . In these patients, the uEV abundances of pNCC and pNKCC2 were increased three-to fourfold. In addition, the pNKCC2-to-total NKCC2 ratio was increased only in the patients with CS and suppressed RAAS. Although the differences in NHE3 between patients with CS and healthy participants were statistically significant, this result was largely due to the strong signals in patients 1 and 6. We also observed a trend toward higher Na + -K + -ATPase abundance in uEVs from patients with a nonsuppressed RAAS, but this did not reach statistical significance. None of the other analyzed proteins in uEVs showed significant differences in abundance, including aquaporin-2, Rac1, and prostasin.
Serum potassium determines sodium cotransporter status in uEVs
Although within the normal range, serum potassium was significantly lower in patients with CS and suppressed RAAS (Table 1) . Serum potassium has recently been recognized as an important driver of NCC activity (37, 38) . Therefore, we analyzed the correlations between serum potassium and aldosterone, NCC, pNCC, and pNKCC2 (Fig. 3) . Although serum potassium and aldosterone showed a positive correlation, it seems unlikely that the normal serum potassium concentrations suppressed aldosterone. Of interest, serum potassium correlated negatively with NCC, pNCC, and pNKCC2 abundances in uEVs. No correlation was observed between urinary cortisol levels, renin, aldosterone, and transporter abundances (data not shown).
Effect of treatment
In seven patients, uEVs were analyzed before and after successful treatment of CS (Fig. 4) . NHE3 decreased in all patients with CS, although the decrease in the patients with a suppressed RAAS was of borderline significance (P = 0.08). In patients with suppressed RAAS, the abundances of pNKCC2, NCC, and pNCC decreased significantly after treatment (;threefold to fivefold). The seven patients received the following treatments for CS. Four of five patients with newly diagnosed Cushing disease underwent transsphenoidal adenomectomy, which was successful in three patients, whereas one patient was subsequently treated with bilateral adrenalectomy because of persistent hypercortisolism. One patient without a visible adenoma was treated with ketoconazole with normalization of cortisol production. Three patients with recurrent Cushing disease were treated with steroid synthesis inhibitors resulting in biochemical remission. Finally, two patients with adrenal CS underwent an uncomplicated laparoscopic adrenalectomy.
Discussion
The pathogenesis of hypertension in CS is complex and not entirely understood. To further elucidate the mechanism of how hypercortisolism increases blood pressure, we isolated and analyzed uEVs in patients with CS and hypertension to analyze renal sodium transport. We hypothesized that patients with suppressed RAAS are more likely to have increased renal sodium reabsorption by other mechanisms, which may be reflected in uEV transporter status. uEVs are nanosized vesicles that contain all of the major renal sodium transport proteins and reflect their activity in the kidney (19, 20, 39, 40) . Using this approach, we found that only patients with CS and a suppressed RAAS had increased abundances of NCC. Of interest, this activation of NCC appears not to reflect the mineralocorticoid effect of hypercortisolism but rather is an indirect effect induced by a reduced serum potassium concentration. Indeed, potassium has recently been identified as a major driver of NCC activity (37, 38, 41, 42) . Our results agree with findings of recent experimental and clinical studies showing a linear relationship between the serum potassium concentration and NCC expression in kidney and uEVs (41, 43) . This effect of potassium appears to be specific for NCC, and it is therefore unclear whether the observed relation between serum potassium and pNKCC2 can be explained by similar mechanisms (37). Together, this proof-of-principle study provides insight in renal sodium handling during CS and the pathogenesis of hypertension in CS (summarized in Fig. 5 ). Previous studies on hypertension in CS also showed that some patients with CS have a suppressed RAAS, whereas others do not (44) (45) (46) (47) (48) . In our cohort, patients with nonsuppressed RAAS had a higher BMI, which is associated with higher plasma renin and aldosterone levels (49, 50) . In addition to effects on renal sodium reabsorption, hypercortisolism can also increase the peripheral vascular sensitivity to adrenergic agonists (51) and the production of angiotensinogen by the liver (47) . The increased uEV abundances of pNKCC2, pNCC, and NCC in CS observed in this study merit further discussion. The increase of pNKCC2, pNCC, and NCC in uEVs of patients with CS and a suppressed RAAS suggests that increased sodium reabsorption through these transporters contributed to an increase in extracellular fluid volume (and therefore suppression of the RAAS). This may also in part explain the higher estimated glomerular filtration rate. In a new steady state, increased sodium reabsorption is not detectable in 24-hour urine (which reflects dietary intake); this likely explains the similar urinary sodium excretions in patients with or without suppressed RAAS (Table 1 ). In adrenalectomized rats, Velázquez et al. (10) showed that both aldosterone and dexamethasone increased NCCmediated sodium reabsorption fivefold. More recently, Ivy et al. (52) showed that glucocorticoids cause nondipping of blood pressure via NCC activation. Glucocorticoid and mineralocorticoid receptors are expressed in the distal convoluted tubule, and activation of these receptors could therefore explain NCC activation (3). However, recent data indicate that NCC activation may occur indirectly via potassium. For example, Veiras et al. (53) showed that angiotensin II stimulates sodiumpotassium exchange through ENaC and the renal outer medullary potassium channel (ROMK). This results in potassium deficiency and thereby NCC activation (53) . Wolley et al. (43) confirmed this mechanism clinically in patients who were undergoing confirmatory testing for primary aldosteronism using the fludrocortisone suppression test. Similar to our data, they also showed that serum potassium was strongly and negatively correlated with pNCC and NCC in uEVs (43) . Similarly, glucocorticoids may have activated ENaC and ROMK with increased potassium secretion and a decrease in serum potassium (11, 18, 54) . Unfortunately, ENaC is difficult to analyze in uEVs (55) . We used prostasin as a surrogate marker for ENaC but found no consistent effect of glucocorticoids. However, ENaC activation is not universally accompanied by an increase of prostasin in uEVs, as recently shown by Qi et al. (56) . Finally, it is unclear how to explain the increase in pNKCC2. In adrenalectomized rats, Stanton et al. (57) did not observe that glucocorticoids increased sodium reabsorption in the Fig. 2. (B) The log-transformed ODs were analyzed by using a paired t test in which the post-treatment abundances were set at 1. *P , 0.05. Error bars represent standard deviations. OD, optical density. thick ascending limb. Frindt and Palmer (11), however, did show an increase in NKCC2 in dexamethasone-treated rats but did not analyze pNKCC2. Of interest, when transporter activity would be expressed as the ratio between the phosphorylated and total protein abundance (i.e., pNKCC2/NKCC2 and pNCC/NCC), this would favor activation of NKCC2 rather than NCC. One would have expected more severe hypercortisolism in the patients with CS and suppressed RAAS. This might in part be explained by differences in 11b-hydroxysteroid dehydrogenase 2 (11b-HSD2) activity between both patient groups. Studies suggest a positive relation between 11b-HSD2 activity and BMI (58, 59) . Patients with nonsuppressed RAAS in our study had a higher BMI than did those with suppressed RAAS, which may have modulated 11b-HSD2 activity next to possible other factors. We did not measure urinary steroid metabolites to assess 11b-HSD2 activity, but this could be a subject for future studies. The glucocorticoid activation of NCC is well described.
A number of limitations of this study should be mentioned. First, because this was an observational study, we could not discontinue antihypertensive drugs and therefore had to exclude patients already receiving renin-angiotensin inhibitors or diuretics. This resulted in a relatively small number of patients [although similar to numbers in previous uEV studies (43, 56) ]. The patient group was too small to analyze possible sex differences in sodium transporters, as was recently reported (60) . Second, although several groups have shown that transporter analysis in uEVs correlates with their activity in the kidney (19, 20, 39, 40) , this still remains an indirect measure of true transporter activity. We tried to address this by analyzing the phosphoproteins of the transporters, which are generally considered the active forms (21).
In conclusion, our study provides insights in the pathogenesis of hypertension in CS showing that cortisol excess increases renal sodium transporter abundance in uEVs, especially in patients with suppressed RAAS. In addition to excess glucocorticoids, low serum potassium may also contribute to increased renal sodium reabsorption and hypertension in CS. These results may also be relevant for hypertension induced by exogenous glucocorticoids. 
